Agreements

* On September 9, 2013, Oncodesign, a contract research laboratory dedicated to the discovery of new anticancer therapies, and Banook Central Imaging, a company specializing in the centralized reading of medical images, have announced the start of a partnership to expand the use of new approaches in pharmaco-imaging. The partners expect to share expertise, co-promote joint activities and jointly engage in scientific collaboration to standardize image acquisition and analysis protocols in early clinical phases. The various medical imaging procedures (computed tomography, magnetic resonance imaging, positron emission tomography, single-photon emission computed tomography and ultrasound imaging) have become indispensable tools in early-stage development of anticancer compounds. The information they provide about the disease and the effects of molecules is highly valuable in identifying translational markers in preclinical and clinical phases. The partnership between Oncodesign and Banook Central Imaging breaks new ground in the evaluation of anticancer therapies by helping to guide a compound from research laboratory to patient through the pursuit of greater consistency in the imaging protocols used during the development cycle, in accordance with good clinical practice. The first phase of this partnership will last three years. First results are expected by early 2014.

A joint announcement about the partnership will be made at the ESMO (European Society for Medical Oncology) conference to be held in Amsterdam, the Netherlands, from September 27 to October 1.